Squarepoint’s Corvus Pharmaceuticals CRVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.5M Buy
130,023
+85,818
+194% +$1.2M ﹤0.01% 2428
2026
Q2
$660K Sell
44,205
-79,691
-64% -$1.11M ﹤0.01% 3208
2026
Q1
$1.81M Buy
123,896
+19,076
+18% +$304K ﹤0.01% 2250
2025
Q4
$807K Buy
+104,820
New +$827K ﹤0.01% 2794
2025
Q3
– Sell
-138,462
Closed -$554K – 4452
2025
Q2
$554K Buy
138,462
+37,430
+37% +$136K ﹤0.01% 3187
2025
Q1
$321K Buy
101,032
+2,888
+3% +$13.6K ﹤0.01% 3691
2024
Q4
$525K Buy
98,144
+86,064
+712% +$642K ﹤0.01% 3688
2024
Q3
$63.8K Buy
+12,080
New +$43.4K ﹤0.01% 3951
2023
Q3
– Sell
-17,082
Closed -$39.1K – 3848
2023
Q2
$39.1K Buy
+17,082
New +$35.5K ﹤0.01% 3459
2022
Q1
– Sell
-13,118
Closed -$32K – 2936
2021
Q4
$32K Sell
13,118
-6,836
-34% -$26.5K ﹤0.01% 3067
2021
Q3
$97K Buy
+19,954
New +$59.1K ﹤0.01% 2674
2020
Q3
– Sell
-26,418
Closed -$72K – 2534
2020
Q2
$72K Buy
26,418
+1,982
+8% +$5.86K ﹤0.01% 2060
2020
Q1
$52K Buy
+24,436
New +$99.2K ﹤0.01% 1715
2019
Q2
– Sell
-45,785
Closed -$184K – 2412
2019
Q1
$184K Sell
45,785
-27,669
-38% -$117K ﹤0.01% 1952
2018
Q4
$270K Buy
73,454
+22,630
+45% +$154K ﹤0.01% 1550
2018
Q3
$436K Buy
50,824
+35,771
+238% +$358K 0.01% 1363
2018
Q2
$165K Buy
15,053
+1,675
+13% +$18.7K ﹤0.01% 1572
2018
Q1
$154K Buy
+13,378
New +$127K ﹤0.01% 1530

Other funds holding CRVS

Squarepoint's CRVS Position: Q3 2026 in Review

Squarepoint increased its Corvus Pharmaceuticals (CRVS) stake by 194% in Q3 2026, buying an estimated $1.2M and bringing the position to 130,023 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

Squarepoint first reported a position in CRVS in Q1 2018 and has held it in 18 quarters since. The position peaked at $1.81M in Q1 2026. 177 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

  • Squarepoint held 130,023 shares of Corvus Pharmaceuticals worth $1.5M as of Q3 2026.
  • Squarepoint bought 85,818 Corvus Pharmaceuticals shares in Q3 2026, an estimated $1.2M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #2428 holding.
  • Squarepoint first reported a position in Corvus Pharmaceuticals in Q1 2018 and has held it in 18 quarters since.
  • Squarepoint's Corvus Pharmaceuticals position peaked at $1.81M in Q1 2026.
  • 177 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.